The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?
Open accessAbstract
Hypogonadotropic hypogonadism (HH) can be sustained by organic or functional alterations of the hypothalamic-pituitary-testicular axis. Functional HH is related to systemic alterations, such as obesity or chronic inflammatory diseases, but could contribute to a negative course of the illness. For such situation, according to results obtained in infertile women, the administration of selective estrogen receptor modulators (SERMs) has been proposed in males too, with positive results on both metabolic and sexual function. This class of medications increases gonadotropin levels via antagonism to the estrogenic receptor; similar biological effects are also exerted by aromatase inhibitors (AIs), despite different mechanism of action. After a brief review of trials regarding SERMs and AIs use in male HH, we describe the structure and function of the androgen receptor (AR) as a basis for clinical research about compounds able to bind to AR, in order to obtain specific effects (SARMs). The tissue selectivity and different metabolic fate in comparison to testosterone can potentiate anabolic versus androgenic effects; therefore, they might be a valid alternative to testosterone replacement therapy avoiding the negative effects of testosterone (i.e., on prostate, liver, and hematopoiesis). Trials are still at an early phase of investigation and, at the moment, the application seems to be more useful for chronic disease with catabolic status while the validation as replacement for hypogonadism requires further studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the central nervous system, some SERMs, namely clomiphene citrate and tamoxifen, function as antagonists to the estrogen receptor, thereby, inhibiting the negative feedback of estrogen to the hypothalamus and pituitary gland. This results in increased endogenous gonadotropin levels which stimulate testosterone production [4,17,47].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, they require a functional HPG axis and cannot be used in men with organic hypogonadism [47].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Selective estrogen receptor modulators (SERMs) selectively modulate the estrogen receptor leading to variable effects in different tissues.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast to TRT, these drugs preserve fertility.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
The cited source says what the claim attributes to it.
In the citing paper
“Unlike the SERMs clomiphene citrate and tamoxifen, AIs reduce estrogen levels [47].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [47]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 1×
“AR-activated genes comprise KLK3 that encode the prostate-specific antigen (PSA), KLK2, FKBP5, transmembrane protease serine 2 (TMPRSS2), and several other transcripts [39].”
BackgroundTestosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00229 · Cited by 1,736 · cited 1×
“, obesity, metabolic syndrome, diabetes mellitus, and so on) have been suggested [3, 4].”
BackgroundMorishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416 · cited 1×
“Different studies support this view showing severe male osteoporosis in patients affected by mutations of the estrogen receptor or mutations of the aromatase [58, 59].”
BackgroundPharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 1×
“In these conditions, hypogonadism is related to a progressive worsening of the disease, despite an adequate therapy (for instance, the failure of diet in obese men) [5], contributing to the evolution by an unfavourable vicious circle.”
BackgroundMolecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942 · cited 1×
“In human beings, the androgen receptor (MW 110 kDa; 919-920 amino acids) is encoded by the AR gene located on the long arm chromosome X at the locus Xq11- Xq12 [28, 29].”
BackgroundKhosla, S., Amin, S., & Orwoll, E. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0002 · Cited by 930
Tajar, A., Forti, G., O'Neill, T. W., Lee, D. M., Silman, A. J., Finn, J. D., Bartfai, G., Boonen, S., Casanueva, F. F., Giwercman, A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1796 · Cited by 604 · cited 1×
“Hypogonadotropic hypogonadism, also known as secondary hypogonadism, is the most common form of hypogonadism in adult and elderly man [1], related to an absolute or relative defective secretion of gonadotropin-releasing hormone (GnRH) by the hypothalamus and/or gonadotropin secretion by the pituitary gland.”
BackgroundPharmacology of anabolic steroids
Kicman, A. T. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.165 · Cited by 580 · cited 1×
“Some of these are obtained by modification of the steroid structure, but others are nonsteroidal; it is an old concept, the myotrophic/androgenic index [41] as a major tool to evaluate androgen potency.”
BackgroundLubahn, D. B., Joseph, D. R., Sar, M., Tan, J.-A., Higgs, H. N., Larson, R. E., French, F. S., & Wilson, E. M. (1988) · Molecular Endocrinology · doi:10.1210/mend-2-12-1265 · Cited by 570 · cited 1×
“In human beings, the androgen receptor (MW 110 kDa; 919-920 amino acids) is encoded by the AR gene located on the long arm chromosome X at the locus Xq11- Xq12 [28, 29].”
BackgroundEffect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531 · cited 1×
“-e aim to further ameliorate anabolic effects should be on the other hand preferentially pursued for the extended indications to SARM therapy, especially osteoporosis in elderly men [43, 44], glucocorticoid-induced osteoporosis [43], HIV sarcopenia and cancer cachexia [45], anaemia, and muscular dystrophies [42, 46].”
Background
Research works printed but not linked: 7
- 2019, Journal of Andrology, 12, 258
- 10.1210/mend.9.2.7776971 · doi:10.1210/mend.9.2.7776971 · Paper page
- 10.1210/jcem.84.10.6122 · DOI · Paper page
- 10.1210/jcem.84.8.588510.1210/jc.84.8.2647 · doi:10.1210/jcem.84.8.588510.1210/jc.84.8.2647
- 10.1210/jcem.83.9.507910.1210/jc.83.9.3155 · doi:10.1210/jcem.83.9.507910.1210/jc.83.9.3155
- 10.1210/jcem.86.1.712610.1210/jc.86.1.192 · doi:10.1210/jcem.86.1.712610.1210/jc.86.1.192
- 2002, Journal of Musculoskeletal and Neuronal Interactions, 2, 222
Cited by
Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
Ide, V., Vanderschueren, D., & Antonio, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010021 · Cited by 101
“However, they require a functional HPG axis and cannot be used in men with organic hypogonadism [47].”
BackgroundInfluentialShpakov, A. O. (2021) · Pharmaceuticals · doi:10.3390/ph14010042 · Cited by 91
Annual banned‐substance review: Analytical approaches in human sports drug testing 2019/2020
Thevis, M., Kuuranne, T., & Geyer, H. (2020) · Drug Testing and Analysis · doi:10.1002/dta.2969 · Cited by 35
Xie, Y., Tian, Y., Zhang, Y., Zhang, Z., Chen, R., Li, M., Tang, J., Bian, J., Li, Z., & Xu, X. J. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114119 · Cited by 31
Lisco, G., Giagulli, V. A., Tullio, A. D., Pergola, G. D., Guastamacchia, E., & Triggiani, V. (2020) · Geriatrics · doi:10.3390/geriatrics5040076 · Cited by 28
Self-citation
Metadata
- Authors
- Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A.
- Affiliations
- University of Bari Aldo Moro (IT)
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Silvestrini, Andrea
- Mancini, Antonio
- ORCID
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2020-01-21
- Volume
- 2020
- Pages
- 1-9
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- PMC
- PMC7201459
- OpenAlex
- W3001691037
- Cited by
- 14
- References
- 68
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 1 · 2020: 3
- FWCI
- 0.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- male hypogonadism, selective estrogen receptor modulators, selective androgen receptor modulators, aromatase inhibitors, testosterone replacement therapy, androgen receptor, hypothalamic-pituitary-testicular axis, obesity, chronic inflammatory diseases, gonadotropin secretion, anabolic effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism? https://app.cochat.ai/papers/10.1155/2020/9649838
- The paper
- Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A. (2020). Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism? International Journal of Endocrinology. https://doi.org/10.1155/2020/9649838
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.